News & Updates

Treatment with abrocitinib is both safe and effective in patients with moderate-to-severe atopic dermatitis (AD), regardless of prior dupilumab response status, a study has shown.

The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.

For male patients with inflammatory bowel disease (IBD), treatment with biologic, thiopurine, or methotrexate does not appear to promote impairments in fertility or adverse pregnancy outcomes, according to a study.

COVID-19 vaccination-induced uveitis is uncommon, with cases mostly self-limiting and showing good responses to treatment with no long-term sequelae, according to a Singapore study. However, reactivation of such infections appears to occur at a higher proportion in Southeast Asia, where viral and toxoplasma infections are more common.

Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.

In the secondary analysis of the phase III ADVANCE trial, responder rates were markedly higher with atogepant irrespective of dose than with placebo in adults with migraine.

Chronic obstructive pulmonary disease (COPD) patients initiating treatment with a long-acting muscarinic antagonist (LAMA) plus a long-acting β2-agonist (LABA) tend to have higher disease severity than those who are started on LAMA, according to real-world data from Singapore. However, there are as many patients who experience clinical worsening in the LAMA group as there are in the LAMA+LABA group.

People who inject drugs (PWID) and are receiving treatment for hepatitis C virus (HCV) show a substantial decline in liver disease and mortality, according to a study.